July 3, 2007, Halifax, Nova Scotia – Origin BioMed Inc., a manufacturer of
over-the-counter topical drug products, announced today it has secured $3.8
million in funding, led by Calgary-based Avrio Ventures Limited Partnership,
along with co-investors Nova Scotia Business Inc. (NSBI) Venture Capital and
several private individuals. This new investment will help drive the company’s
North American market expansion, placing Origin’s leading diabetic neuropathy
products – including Neuragen®, a topical oil for fast-acting relief of diabetic foot
pain – on American drug store shelves. Origin will also open a US office as part
of this expansion.